On 2015 Jan 09, GEORGE BLANCK commented:
Stochastic aspects of cancer development:
The article by Tomasetti and Vogelstein (1) has helped add another dimension to the study of cancer development, most often driven by researching intracellular signaling pathway malfunctions and microenvironment effects, including inflammation. In fact, there are many molecular aspects cancer development that are governed by a random chance component of biological processes. First, genes that form cancer fusion genes are comparatively large (2, 3), presumably due to large introns providing for many opportunities for a productive recombination that leads to a chimeric protein, requiring of course intact exons, but in most cases, no particular retention of intron sequences. Interestingly, one of the smallest cancer fusion genes, EWSR1 (2), occurs in Ewing’s sarcoma, among the rarest cancers.
The sequential order of mutations, originally thought to represent requirements for an ordered process of acquisition of cancer hallmarks, could also be (at least partially) explained on the basis of gene size (4), with metastasis suppressor genes, which cannot be readily distinguished from classical tumor suppressor genes via signal pathway exclusivity, being comparatively small (4) and thus potentially less likely to be mutated early in cancer development. It is not inconceivable that certain functions are required to precede others in cancer development. For example, lack of apoptosis remains a good candidate for preceding metastasis (4). However, stochastic functions are likely to be a major basis for sequential mutations, and this underlying factor is consistent with the more recent appreciation of signal pathway degeneracy in cancer, reflected in the many alternative pathways discovered in drug-resistant cells and by many other aspects of cancer research indicating pathway degeneracy. In short, there is less opportunity to argue for an ordered acquisition of cancer hallmarks if the underlying mechanisms do not credibly distinguish such hallmarks (4, 5).
Interestingly, cytoskeletal related proteins represent some of the largest coding regions in the human genome, and not surprisingly cytoskeletal related protein coding regions are very commonly found mutated in the cancer genome atlas (6). Thus, mutant cytoskeletal proteins may be stochastically inevitable, which raises several interesting questions related to the mutational basis of cancer development and cell shape. First, do mutant cytoskeletal related proteins have a high propensity for a dominant negative impact on the cytoskeleton, as do mutant forms of collagen polypeptides in Osteogenesis imperfecta, where cartilage polymer formation is disrupted by a mutant collagen molecule from just one allele? Second, is the oft-reported, and decades-old connection between metastasis and spherical cells (7, 8) due to mutant forms of the cytoskeleton, which provide for cell rounding and detachment and thus distant circulation? And finally, is the oft-reported, but much more recent connection between spherical cells and drug resistance (9-11) due to common, mutant cytoskeletons that essentially lead to a decreased surface area to volume ratio, in turn leading to reduced intracellular drug concentrations?
As noted (1), the more cell divisions, the more errors, due to intrinsic DNA replication error rates. It remains to be seen to what extent this conclusion is relevant to cancer development in specific settings. Cell division rates may vary with circumstance, particularly over a lifetime, due to such events as wound healing, surgery or radiation or accidents that remove replicative tissue, lymphocyte replication in infections and vaccinations, etc.
The appreciation of probabilistic functions governing cancer development should lead to fresh research avenues, as did the understanding of the roles of signal pathway malfunctions and inflammation. Can screening be organized with more refined purposes and more cost-efficiency, when accounting for the stochastic aspect of mutation occurrence and cancer development? For example, it is likely that point mutations leading to an activating oncoprotein are relatively rare and will have a relatively high probability of being followed by a mutation in a large tumor suppressor gene. On the other hand, many (apparent) cancers that represent large gene mutations may not require aggressive treatment, because the chance of a single base change leading to an activating oncoprotein, needed for aggressive cancer, may be minimal (12).
And, how do stochastic events compare to differences in DNA repair polymorphisms or other rate-limiting aspects of mutation occurrence, such as the differences in mutation rates between heterochromatin and transcriptionally active regions (13)? For example, are there long-term, disease-free smokers because of luck or because of highly efficient repair mechanisms?<br>
References to PubMed comment, January 9, 2015:
1. PMID: 25554788.
2. PMID: 19446742.
3. PMID: 23162078.
4. PMID: 22701759.
5. PMID: 25450826.
6. PMID: 25451318.
7. PMID: 6256751.
8. PMID: 7000337.
9. PMID: 24409314.
10. PMID: 24112388.
11. PMID: 24821384.
12. PMID: 25294886.
13. PMID: 25456125.
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.